about
Effect of Subchronic Intravenous Morphine Infusion and Naloxone-Precipitated Morphine Withdrawal on P-gp and Bcrp at the Rat Blood-Brain BarrierMethadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activityLiquid chromatography high resolution mass spectrometry for the determination of baclofen and its metabolites in plasma: Application to therapeutic drug monitoring.Urinary glycol ether metabolites in women and time to pregnancy: the PELAGIE cohortBlood and urinary levels of metals and metalloids in the general adult population of Northern France: The IMEPOGE study, 2008-2010.The effect of morbid obesity on morphine glucuronidation.Exposure to glycol ethers in a population of French men evaluated by measurement of urinary alkoxycarboxylic acids.Determination of total and unbound concentrations of lopinavir in plasma using liquid chromatography-tandem mass spectrometry and ultrafiltration methods.Tumor necrosis factor-alpha stimulates ICAM-1 expression in human vascular smooth muscle cells.Exposure during pregnancy to glycol ethers and chlorinated solvents and the risk of congenital malformations.Spectrophotometric, spectrofluorimetric, HPLC and CZE determination of mirtazapine in pharmaceutical tablets.Separation of new antidepressants and their metabolites by micellar electrokinetic capillary chromatography.Rapid and simple determination of selenium in blood serum by inductively coupled plasma-mass spectrometry (ICP-MS).A fatal case of mercuric cyanide poisoning.Mechanisms of tramadol-related neurotoxicity in the rat: Does diazepam/tramadol combination play a worsening role in overdose?Usefulness of plasma drug monitoring in severe baclofen poisoning.Prevalence of psychoactive substances in truck drivers in the Nord-Pas-de-Calais region (France).[Use of illicit substances in the workplace].Oral Morphine Pharmacokinetic in Obesity: The Role of P-Glycoprotein, MRP2, MRP3, UGT2B7, and CYP3A4 Jejunal Contents and Obesity-Associated Biomarkers.Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lunIs extracorporeal treatment useful for managing severe baclofen poisoning? – The debate is still openUrinary biomarkers of exposure to glycol ethers and chlorinated solvents during pregnancy: determinants of exposure and comparison with indirect methods of exposure assessmentMonocyte adherence to endothelial cells in patients with atherosclerosis: relationships with risk factorsEffect of low density lipoprotein on monocyte adhesiveness to endothelial cells in vitroInfluence of lipophilicity on the protein binding affinity of cephalosporinsColumn-switching high-performance liquid chromatographic determination of vancomycin in serumQuantitative analysis of polymerase chain reaction products using biotinylated dUTP incorporation[Side-effects during treatment of rheumatoid arthritis with methotrexate]Determination of flunitrazepam in plasma by liquid chromatographyMonocyte/macrophage recruitment and expression of endothelial adhesion proteins in human atherosclerotic lesionsDetermination of urea, allantoin and lysine pyroglutamate in cosmetic samples by hydrophilic interaction chromatographyComparison of high-performance liquid chromatography and capillary zone electrophoresis for the determination of parabens in a cosmetic productUrinary arsenic concentrations and speciation in residents living in an area with naturally contaminated soils[Assessment of occupational exposure to ortho-toluidine using gas chromatography-mass spectrometry]Arsenic urinary concentrations in children living in a naturally arsenic contaminated areaBaclofen-induced encephalopathy in overdose - Modeling of the electroencephalographic effect/concentration relationships and contribution of tolerance in the ratIs R(+)-Baclofen the best option for the future of Baclofen in alcohol dependence pharmacotherapy? Insights from the preclinical sideAssessment of Extracorporeal Treatments in Poisoning criteria for the decision of extracorporeal toxin removal in lithium poisoning
P50
Q28579584-9E12C71A-52A0-4116-B240-A468FF50C987Q35684822-A8AE9B5E-3CA0-4595-8791-E21FE424DAF6Q36249705-1151BF69-A6DE-4660-B0E8-DC99B08B0DEFQ37241795-A8AB4E55-1E37-4082-BEDF-3DCC59ED1C63Q39118874-4BE23CB8-1D3D-424E-A6C6-6B7FE6E2C8EEQ39408617-0CA69D3A-3D25-45B8-8BBF-D908102B8A8FQ40507945-73775EEC-B766-492A-B727-8FEB13FB44B7Q42204623-5FF42C35-FE86-4FA3-BAA2-7361027E398FQ42497494-9B33AB8D-77AE-4458-B7BE-E25FC6A9EB19Q43465668-09BC46A0-0582-4BFB-A673-786369FE5014Q43945095-C256D2E0-AE93-45E6-BAAE-637F6A15CEB1Q43996635-AEBC6445-CEC9-4183-AAAB-80C71DDD95EFQ44391521-C67F8339-D667-4BEC-A68B-4DA07C3E0E1EQ44968250-3C618755-F54C-428A-B0EA-D603FC9017A3Q47387570-8FA0ED8D-F69A-4F0D-9991-C21D0347AE27Q48073798-69786F39-8C03-488E-B781-6EBD29DFD362Q48607423-BA34D92E-5DE2-4DC9-9CD7-2825D268ECC6Q52300332-B611C274-DC20-489A-A7A0-7FEAD655358BQ53802072-076A9D04-D5FC-49B8-9E09-A284F069D821Q54976670-6FD2191E-EBD8-4061-9F56-5CB636AB4DFAQ57016600-4DB10618-8166-4FE5-95EC-ADFE022BC9E3Q57998432-79F0F2D3-9630-4F97-964D-0F53D7CC54D5Q70493538-6B6BA2A6-A43E-4632-9CE4-C7380681A61AQ70630748-70AF3D10-D4C2-4AAE-8FEC-049549E7D230Q70958872-8473E56B-4BB4-44FD-907A-8CD261FCDEC1Q72186760-1432192A-6AEA-4279-914D-D340A02DCD47Q72231388-49477A63-64FC-47BC-8492-C51DF72A1AEFQ72386734-4A5B50B2-9318-4E86-9446-BCC0E6D3444EQ72859710-C65759DE-0694-4F1C-A3B9-C22ED1412172Q73284496-F7AA8ABA-F7C6-46FB-86AE-3201C0C71841Q74019239-9EA336E6-B474-4524-88E1-A0B049B5ED2FQ74277182-630AF94C-B784-4DF7-89B2-942F65D94C8DQ82215201-86DAC9E8-D70D-4B7A-971F-D2AD54BDC18DQ83341376-06D76AB8-B41C-47C3-8DC7-501B15EB9149Q84581972-E6C9FCB5-8A07-4F3F-8467-2D777F7DEBE6Q88758234-7040CE0C-382F-494A-A879-DF4ED6565C57Q90134905-43EB6A9E-D664-48C3-929C-E7B2664304B1Q92398552-DA4385B9-2CAE-493B-8495-BB41DF4016EB
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Laurence Labat
@ast
Laurence Labat
@en
Laurence Labat
@es
Laurence Labat
@nl
Laurence Labat
@sl
type
label
Laurence Labat
@ast
Laurence Labat
@en
Laurence Labat
@es
Laurence Labat
@nl
Laurence Labat
@sl
prefLabel
Laurence Labat
@ast
Laurence Labat
@en
Laurence Labat
@es
Laurence Labat
@nl
Laurence Labat
@sl
P1053
L-6150-2017
P106
P31
P3829
P496
0000-0001-8291-3054